What is Foldax?
Foldax is at the forefront of cardiac care innovation, developing the TRIA heart valves designed for enhanced durability and broader patient accessibility. Leveraging advanced biocompatible polymers and precision robotic manufacturing, the company aims to overcome the limitations of existing heart valve technologies. Their approach is particularly beneficial for younger patients and those affected by conditions such as rheumatic heart disease. While the TRIA Mitral Valve has gained approval in India, its status in the United States remains investigational, highlighting the ongoing development and regulatory pathway for this groundbreaking technology.
How much funding has Foldax raised?
Foldax has raised a total of $34M across 4 funding rounds:
Series A
$3.4M
Series B
$10.3M
Debt
$350K
Series D
$20M
Series A (2016): $3.4M, investors not publicly disclosed
Series B (2018): $10.3M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Series D (2020): $20M featuring MemorialCare, Caltech, BioStar Capital, Sayan Bioventures, Angel Physicians Fund, and Kairos Ventures
Key Investors in Foldax
MemorialCare
MemorialCare is a healthcare system with a long-standing history, operating hospitals and outpatient facilities, indicating a strategic interest in healthcare infrastructure and patient care services.
Kairos Ventures
Kairos Ventures appears to be an investment firm with a focus on companies that promote personal growth and well-being, suggesting a potential alignment with Foldax's mission to improve patient health outcomes.
Caltech
Caltech, a renowned academic and research institution, likely participated as an early-stage supporter or through technology transfer, indicating a commitment to scientific advancement and innovation.
What's next for Foldax?
The recent major strategic investment positions Foldax for a significant scaling phase. This capital injection is anticipated to fuel advancements in clinical trials, regulatory submissions, and manufacturing capacity expansion. With a focus on broadening patient access to its TRIA heart valves, Foldax is poised to make substantial inroads into both domestic and international markets. The company's commitment to utilizing cutting-edge materials and manufacturing processes suggests a continued trajectory of innovation and market leadership in the cardiovascular device sector.
See full Foldax company page
